Insight into the dazzling impact of insulin in cellsMEDIA RELEASE: 21 May 2013 Garvan scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes. The breakthrough study is now published in the early online edition of the prestigious journal Cell Metabolism. More
Garvan and St Vincent’s Welcome Critical Prostate Cancer Funding for The Kinghorn Cancer CentreMEDIA RELEASE: 17 May 2013 Both the Garvan Institute of Medical Research and St Vincent’s Hospital have welcomed the Federal Government’s foreshadowed announcement in this week’s budget of $5.5 million over 4 years to The Kinghorn Cancer Centre’s National Prostate Cancer Research Centre. More
Garvan and Cancer Therapeutics CRC Pty Ltd License Pan-Kinase Binding Agent to SYNkinaseMEDIA RELEASE: 16 May 2013 Garvan and Cancer Therapeutics CRC Pty Ltd have signed a licence agreement with SYNkinase Pty Ltd to develop and market a unique Pan-Kinase Binding Agent to help screen human cells and tissues and identify potential drug targets in diseased states. The novel agent has the unique ability to detect a large proportion of the protein kinase family, giving it the potential to become a remarkable research tool for life scientists around the globe. More
Evidence that brains re-wire themselves following damage or injuryMEDIA RELEASE: 14 May 2013 Neuroscientists from Garvan, in collaboration with learning theorists from the University of California Los Angeles (UCLA), have advanced our understanding of brain plasticity by showing that the brain forms complex new circuits after damage, often far from the damaged site, to compensate for lost function. This is the first demonstration of such circuit plasticity. More
John Schubert becomes Chairman of GarvanMEDIA RELEASE: 01 May 2013 The Garvan Institute of Medical Research is delighted to announce the appointment this week of Dr John Schubert AO to its Board by the Governor of New South Wales, Her Excellency Professor Marie Bashir AC CVO, and his subsequent election by the Board as its Chair. He succeeds Mr Bill Ferris AC, Garvan Chairman since 2001. More
The connection between faulty neural activation and schizophreniaMEDIA RELEASE: 28 Apr 2013 By studying what happens in the normal brain when neurons fire, Australian scientists have been able to identify a finely and dynamically regulated process. They also describe how dysfunction of this process is associated with schizophrenia. The process involves a specific class of genes known as ‘long non-coding RNAs’. More
Obesity may explain reduced bone fracture worldwideMEDIA RELEASE: 10 Apr 2013 A Garvan study shows that women – but not men – with more abdominal fat are less at risk of bone fracture. This may explain why global rates of fracture are declining at the same time as obesity is increasing. The data come from the ongoing Dubbo Osteoporosis Epidemiology Study (DOES). More
Forget about plaque when diagnosing Alzheimer’s DiseaseMEDIA RELEASE: 02 Apr 2013 A Garvan study has shown that plaque, long considered to be the hallmark of Alzheimer’s disease, is one of the last events to occur in the Alzheimer’s brain. This finding will impact the current debate about how best to diagnose and treat Alzheimer’s disease. More
06 Sep 2013Scientific
FRACTURE RISK CALCULATOR
Based on data from the 18-year Dubbo Osteoporosis Epidemiology Study. For men and women 60 years and over to assess their individual risk of fracture.
AUSTRALIAN PANCREATIC CANCER GENOME INITIATIVE
Garvan is involved in the Australian arm of the The International Cancer Genome Consortium – by investigating pancreatic cancer. For more information click here.
St Vincents and Mater Health Sydney Research Symposium
6 September 2013
This annual Symposium draws upon research from institutions across the St Vincent's Campus.